Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by 89bio, Inc.

< Previous 1 2 Next >
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio to Participate in the 7th Annual Evercore HealthCONx Conference
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio Reports Third Quarter 2024 Financial Results and Corporate Updates
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio to Participate in the UBS Global Healthcare Conference
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting® 2024
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio to Participate in the H.C. Wainwright 8th Annual MASH Investor Conference
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio to Participate in Upcoming Investor Conferences
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio Appoints Francis Sarena as Chief Operating Officer
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio Reports Second Quarter 2024 Financial Results and Corporate Updates
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio Appoints Charles McWherter, Ph.D., to its Board of Directors
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio to Participate in the BofA Securities 2024 Health Care Conference
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio to Host Key Opinion Leader Webinar on Pegozafermin’s Opportunity in Advanced MASH
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.